J. Dutcher

发表

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma.

David McDermott, R. Figlin, R. Motzer, 2007, The New England journal of medicine.

Therapeutic Cytapheresis, Plasmapheresis, and Plasma Exchange in Neoplastic Diseases of the Blood

J. Dutcher, Janice P. Dutcher, 2013 .

Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma.

G. Wilding, B. Rini, G. Hudes, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Renal parenchymal tumors and lymphoma in the same patient: Case series and review of the literature

J. Dutcher, A. Kunthur, P. Wiernik, 2006, American journal of hematology.

Cardiovascular toxicity with cancer chemotherapy.

W. Frishman, J. Dutcher, D. Keefe, 1996, Current problems in cancer.

Cardiovascular toxicity with cancer chemotherapy.

W. Frishman, J. Dutcher, D. Keefe, 1997, Current problems in cardiology.

Phase I study of recombinant human CD40 ligand in cancer patients.

J. Gribben, J. Dutcher, J. Anderson, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.

R. Motzer, B. Duclos, G. Hudes, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diagnosis and Treatment of Early Melanoma: NIH Consensus Development Panel on Early Melanoma

Gary S. Rogers, Natale Cascinelli, Lowell A. Goldsmith, 1992 .

Transcriptional profiles in peripheral blood mononuclear cells prognostic of clinical outcomes in patients with advanced renal cell carcinoma.

Manuel Hidalgo, Donna K Slonim, Walter M Stadler, 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.

Acute renal dysfunction during interleukin-2 treatment: suggestion of an intrinsic renal lesion.

D. Feinfeld, J. Dutcher, L. Freeman, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Manish R. Patel, Charles J. Vaske, Joe Y. Chang, 2016, Journal for Immunotherapy of Cancer.

Handbook of Hematologic and Oncologic Emergencies

J. Dutcher, P. Wiernik, 1987, Springer US.

Hyperleukocytosis in Leukemia—An Emergency

J. Dutcher, 1987 .

Induction of Adaptive Anti-HER2/neu Immune Responses in a Phase 1B/2 Trial of 2B1 Bispecific Murine Monoclonal Antibody in Metastatic Breast Cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group

W. Wood, H. Borghaei, L. Weiner, 2007, Journal of immunotherapy.

A Review of Evidence-Based Treatment of Stage IIB to Stage IV Melanoma

J. Dutcher, S. Eapen, 2005, Cancer investigation.

Survival more than 19 years after the diagnosis of accelerated phase of chronic myelocytic leukemia.

J. Dutcher, E. Paietta, J. Racevskis, 2011, Clinical advances in hematology & oncology : H&O.

Encouraging survival with erlotinib in advanced papillary renal cell carcinoma (pRCC): Final results from Southwest Oncology Group study 0317

W. Samlowski, R. Nagle, P. Mack, 2008 .

Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families

J. Dutcher, Leticia Varella, P. Wiernik, 2016, Familial Cancer.

20th‐Century Advances in Drug Therapy in Oncology—Part II

J. Dutcher, P. Wiernik, Y. Novik, 2000, Journal of clinical pharmacology.

An Eastern Cooperative Oncology Group phase I trial of all-trans-retinoic acid and interferon-alpha: E2Y92

D. Neuberg, J. Schiller, M. Levitt, 2004, Investigational New Drugs.

Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12 – Associated Toxicity and Interferon-g Production

J. Leonard, M. Atkins, J. Sosman, 1997 .

Biologic response modifiers in gynecologic malignancies.

S. Wadler, J. Dutcher, P. Wiernik, 1988, The Yale journal of biology and medicine.

NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma

J. Wright, J. Dutcher, P. Christos, 2020, Investigational New Drugs.

Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized

J. Dutcher, C. Schiffer, J. Aisner, 1981 .

Alloimmunization following platelet transfusion: the absence of a dose- response relationship

C. Schiffer, J. Dutcher, C. Schiffer, 1981 .

A randomized trial of leukocyte-depleted platelet transfusion to modify alloimmunization in patients with leukemia.

J. Dutcher, C. Schiffer, J. Reilly, 1983, Blood.

Lymphocytotoxic antibody is a predictor of response to random donor platelet transfusion

J. Dutcher, C. Schiffer, J. Aisner, 1983, American journal of hematology.

Lymphomas following cardiac transplantation. Case report and review of the literature

J. Dutcher, P. Wiernik, N. Sklarin, 1991, American journal of hematology.

Clinical impact of multidrug resistance in acute leukemia.

J. Dutcher, P. Wiernik, 2002, Leukemia research.

Objective response of multiple myeloma to cyclosporin A.

J. Dutcher, D. Rosenstreich, E. Paietta, 1994, Leukemia & lymphoma.

Therapeutic potential of curcumin in prostate cancer—IV: Interference with the osteomimetic properties of hormone refractory C4‐2B prostate cancer cells

J. Dutcher, T. Dorai, P. Wiernik, 2004, The Prostate.

Adjuvant H igh-Dose B olus I nterleukin-2 f or P atients W ith High-Risk R enal C ell C arcinoma: A C ytokine W orking G roup Randomized T rial

R. Figlin, M. Atkins, B. Redman, 2003 .

Revisiting the orthopaedic management of metastatic renal cell carcinoma: rationale for a more aggressive approach

J. Dutcher, Jonathan Morris, David S. Geller, 2013 .

Preclinical and clinical evaluations of ABX-EGF, a fully human anti-epidermal growth factor receptor antibody.

R. Figlin, A. Belldegrun, J. Crawford, 2004, International journal of radiation oncology, biology, physics.

Phase I trial of cyclophosphamide, doxorubicin, and 5-fluorouracil plus interferon-alpha 2b in patients with advanced breast cancer.

N. Robert, J. Sparano, S. Wadler, 1993, Cancer research.

CT of malignant pleural mesothelioma.

J. Dutcher, S. Mirvis, J. Aisner, 1983, AJR. American journal of roentgenology.

Targeted agents in metastatic Xp11 translocation/TFE3 gene fusion renal cell carcinoma (RCC): a report from the Juvenile RCC Network.

P. Camparo, L. Boccon-Gibod, B. Escudier, 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis

J. Dutcher, J. Knox, S. Bracarda, 2013, British Journal of Cancer.

A pilot study of carboplatin and mitoxantrone in blast crisis of chronic myeloid leukemia

J. Dutcher, E. Paietta, B. Gaynor, 2010, Medical oncology.

Commentary (Dutcher/Wiernik): Current Management of Acute Lymphoblastic Leukemia in Adults

J. Dutcher, P. Wiernik, 1995 .

Acute leukemia in a patient cured of diffuse histiocytic lymphoma

J. Dutcher, P. Wiernik, 2004, Journal of Cancer Research and Clinical Oncology.

Randomized phase III trial of treatment with high-dose interleukin-2 either alone or in combination with interferon alfa-2a in patients with advanced melanoma.

R. Fisher, M. Atkins, G. Weiss, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Outpatient biochemotherapy with interleukin-2 and interferon alfa-2b in patients with metastatic malignant melanoma: results of two phase II cytokine working group trials.

R. Fisher, J. Sosman, G. Weiss, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical trial experience with temsirolimus in patients with advanced renal cell carcinoma.

M. Atkins, A. Berkenblit, B. Rini, 2009, Seminars in oncology.

Probable veno-occlusive disease after treatment with gemtuzumab ozogamicin in a patient with acute myeloid leukemia and a history of liver transplantation for familial hemochromatosis

J. Dutcher, D. Jain, P. Wiernik, 2003, Medical oncology.

A Phase II Study of Bevacizumab and High-dose Interleukin-2 in Patients With Metastatic Renal Cell Carcinoma: A Cytokine Working Group (CWG) Study

M. Atkins, J. Sosman, M. Regan, 2013, Journal of immunotherapy.

Fatal Intra-Alveolar Hemorrhage After Rituximab in a Patient with non-Hodgkin Lymphoma

J. Dutcher, P. Wiernik, S. Oiseth, 2004, Leukemia & lymphoma.

Alloimmunization prevents the migration of transfused indium-111-labeled granulocytes to sites of infection.

J. Dutcher, J. Aisner, P. Wiernik, 1983, Blood.

Kidney cancer: The cytokine working group experience (1986–2001)

M. Atkins, J. Sosman, G. Weiss, 2001, Medical oncology.

Kidney cancer: The cytokine working group experience (1986–2001)

M. Atkins, J. Sosman, G. Weiss, 2001, Medical oncology.

Concurrent phase I trials of intravenous interleukin 6 in solid tumor patients: reversible dose-limiting neurological toxicity.

R. Fisher, M. Atkins, J. Sosman, 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase 3, randomized, 3-arm study of temsirolimus (TEMSR) or interferon-alpha (IFN) or the combination of TEMSR + IFN in the treatment of first-line, poor-risk patients with advanced renal cell carcinoma (adv RCC).

R. Figlin, M. Carducci, G. Hudes, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Potentiation of Antiproliferative Effects of Monoclonal Antibody Lym‐1 and Immunoconjugate Lym‐1‐gelonin on Human Burkitt's Lymphoma Cells with γ‐Interferon and Tumor Necrosis Factor

B. Diamond, M. Rosenblum, J. Dutcher, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Human breast carcinoma cells synthesize a protein immunorelated to platelet glycoprotein-Ib alpha with different functional properties.

J. Dutcher, E. Paietta, P. Etkind, 1997, The Journal of laboratory and clinical medicine.

Mammalian Target of Rapamycin Inhibition

J. Dutcher, 2004, Clinical Cancer Research.

Initial results from ASSURE (E2805): Adjuvant sorafenib or sunitinib for unfavorable renal carcinoma, an ECOG-ACRIN-led, NCTN phase III trial.

J. Manola, K. Flaherty, M. Atkins, 2015 .

Incidence of thrombocytopenia and serious hemorrhage among patients with solid tumors

J. Dutcher, C. Schiffer, J. Aisner, 1984, Cancer.

Interleukin-2 therapy in patients with metastatic malignant melanoma: a phase II study.

J. Doroshow, M. Sznol, J. Abrams, 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of interleukin-2 on some micronutrients during adoptive immunotherapy for various cancers.

D. Petrylak, J. Dutcher, S. Marcus, 1992, Journal of the American College of Nutrition.

Platelet and Granulocyte Transfusion

J. Dutcher, 2013 .

A Phase II Study of 13-cis Retinoic Acid Plus Interferon α-2a in Advanced Stage Penile Carcinoma: An Eastern Cooperative Oncology Group Study (E3893)

J. Manola, G. Wilding, Jie Huang, 2003, Cancer investigation.

Overall survival by clinical risk category for high dose interleukin-2 (HD IL-2) treated patients with metastatic renal cell cancer (mRCC): data from the PROCLAIMSM registry

N. Agarwal, M. Fishman, G. Daniels, 2019, Journal of Immunotherapy for Cancer.

High dose interleukin-2 (Aldesleukin) - expert consensus on best management practices-2014

M. Atkins, J. Dutcher, H. Kaufman, 2014, Journal of Immunotherapy for Cancer.

Current status of interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma.

J. Dutcher, 2002, Oncology.

Adjuvant radiotherapy for breast cancer as a risk factor for the development of lung cancer

J. Sparano, J. Dutcher, P. Wiernik, 1994, Medical oncology.

Interleukin-2 and lymphokine-activated killer cell therapy of solid tumors: analysis of toxicity and management guidelines.

R. Fisher, M. Atkins, J. Doroshow, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Families with both Hodgkin lymphoma and multiple myeloma in their pedigrees.

J. Dutcher, P. Wiernik, Dona Wickramasinghe, 2015, Clinical advances in hematology & oncology : H&O.

Interleukin‐2 enhances biopterins and catecholamines production during adoptive immunotherapy for various cancers

D. Petrylak, J. Dutcher, S. Marcus, 1989, Cancer.

Porphyria cutanea tarda in a patient with acute leukemia

J. Dutcher, P. Wiernik, P. Wiernik, 1986, American journal of hematology.

Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Long-term outcomes in first-line patients (pts)

R. Figlin, C. Ryan, R. Bukowski, 2007 .

Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2

Douglas B. Johnson, A. Alva, J. Dutcher, 2021, Journal of Investigative Medicine.

Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition

M. Fishman, S. Patel, G. Daniels, 2019, Journal of Immunotherapy for Cancer.

A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma

R. Sullivan, J. Kirkwood, S. Patel, 2016, Journal of Immunotherapy for Cancer.

Bevacizumab with or without erlotinib in metastatic renal cell carcinoma (RCC).

R. Figlin, K. Flaherty, S. Srinivas, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase IB trial for malignant melanoma using R24 monoclonal antibody, interleukin-2/α-interferon

M. Atkins, J. Sparano, L. Weiner, 1998 .

Disseminated strongyloidiasis with central nervous system involvement diagnosed antemortem in a patient with acquired immunodeficiency syndrome and Burkitts lymphoma

H. Tanowitz, J. Dutcher, S. Marcus, 1990, Cancer.

Interleukins in Cancer Therapy

J. Sparano, J. Dutcher, P. Wiernik, 1994, Clinical Immunotherapeutics.

Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma.

M. Atkins, G. Weiss, M. Sznol, 1989, Cancer treatment reviews.

Phase II Trial of Interleukin 2, Interferon α, and 5-Fluorouracil in Metastatic Renal Cell Cancer: A Cytokine Working Group Study

J. Sosman, G. Weiss, M. Lotze, 2000 .

A randomized phase II trial of continuous infusion interleukin-2 or bolus injection interleukin-2 plus lymphokine-activated killer cells for advanced renal cell carcinoma.

M. Atkins, J. Doroshow, G. Weiss, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboxyamidotriazole in patients with advanced renal cell carcinoma refractory to immunotherapy

J. Manola, G. Wilding, J. Dutcher, 2005, Cancer.

Interleukin-2 based therapy for kidney cancer.

J. Dutcher, 2003, Cancer treatment and research.

Cytoreductive surgery for stage IV renal cell carcinoma.

J. Dutcher, J. Fleischmann, H. Taub, 1995, The Journal of urology.

“Pseudoprogression”: more than semantics

J. Dutcher, 2018, Cancer Immunology, Immunotherapy.

An ECOG Phase II Study of Amonafide in Unresectable or Recurrent Carcinoma of the Head and Neck (PB390)

D. Neuberg, S. Wadler, E. Schwartz, 2004, Investigational New Drugs.

Renal cell carcinoma in patients with a personal or family history of hematologic malignancies.

J. Dutcher, P. Wiernik, 2015, Clinical advances in hematology & oncology : H&O.

Update of a phase 1 study of intravenous CCI-779 given in combination with interferon-α to patients with advanced renal cell carcinoma.

R. Motzer, R. Motzer, L. Galand, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Diastolic blood pressure (dBP) and pharmacokinetics (PK) as predictors of axitinib efficacy in metastatic renal cell cancer (mRCC).

R. Motzer, G. Wilding, B. Rini, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-Term Response and Possible Cure of Patients With B-Cell Malignancies With Dose-Escalated Rituximab

J. Dutcher, P. Wiernik, P. Muxi, 2017, Journal of investigative medicine high impact case reports.

Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): Report of three cases

J. Dutcher, P. Wiernik, D. Alexandrescu, 2005, American journal of hematology.

Adhesive receptors expressed by tumor cells and platelets: novel targets for therapeutic anti-metastatic strategies

J. Dutcher, Lesle Oleksowicz, L. Oleksowicz, 1995, Medical oncology.

Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia.

J. Dutcher, J. Holland, J. Cuttner, 1987, Leukemia.

Atypical clonal T-cell proliferation in infectious mononucleosis

M. Borowitz, J. Dutcher, P. Wiernik, 1996, Medical oncology.

Renal Failure Related to Drugs and Disease

S. Wadler, J. Dutcher, 1987 .

Long‐term survival of a patient with multiple myeloma—A cure? A case report

J. Dutcher, P. Wiernik, P. Wiernik, 1984, Cancer.

Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival.

J. Dutcher, C. Schiffer, P. Wiernik, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Blastic phase of chronic myelogenous leukemia

J. Dutcher, P. Wiernik, Evelyn L Morris, 2005, Current treatment options in oncology.

Pure Red Cell Aplasia Following Interleukin-2 Therapy

J. Dutcher, P. Wiernik, W. Fan, 2016, Journal of investigative medicine high impact case reports.

Significant arrhythmias associated with Interleukin-2 therapy

J. Dutcher, R. Lucariello, P. Wiernik, 2005 .

Interleukin-4 is a pleotropic cytokine with effects on B-cell malignancies.

J. Dutcher, D. Makower, P. Wiernik, 1997, Leukemia research.

Meta-analysis of the association between low-affinity Fc g receptor gene polymorphisms and hematologic and autoimmune diseases

J. Dutcher, P. Wiernik, N. Varshneya, 2001 .

A phase II study of high-dose continuous infusion interleukin-2 with lymphokine-activated killer cells in patients with metastatic melanoma.

R. Fisher, J. Doroshow, G. Weiss, 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Platelet and granulocyte transfusions in cancer patients.

J. Dutcher, 1986, Advances in immunity and cancer therapy.

A phase II study of bevacizumab (B) and high-dose aldesleukin (IL-2) in patients (p) with metastatic renal cell carcinoma (mRCC): A Cytokine Working Group Study (CWGS).

Jeffrey W. Clark, M. Atkins, J. Sosman, 2010 .

Axitinib (AG-013736; AG) in patients (pts) with metastatic renal cell cancer (RCC) refractory to sorafenib

G. Wilding, B. Rini, P. Bycott, 2007 .

Evaluation of natural killer and lymphokine-activated killer (LAK) cell activity in vivo in patients treated with high-dose interleukin-2 and adoptive transfer of autologous LAK cells

J. Dutcher, E. Paietta, J. Walewski, 2004, Journal of Cancer Research and Clinical Oncology.

Temozolomide, thalidomide, and whole brain radiation therapy for patients with brain metastasis from metastatic melanoma

M. Atkins, J. Sosman, G. Weiss, 2008, Cancer.

Effect of histocompatibility factors on pulmonary retention of indium‐111‐labeled granulocytes

G. Johnston, J. Dutcher, C. Schiffer, 1990, American journal of hematology.

Granulocyte transfusion therapy and amphotericin B: Adverse reactions?

J. Dutcher, C. Schiffer, J. Aisner, 1989, American journal of hematology.

Alloimmunization following platelet transfusion: the absence of a dose-response relationship.

J. Dutcher, C. Schiffer, J. Aisner, 1981, Blood.

Platelet Activation Induced by lnterleukin-6: Evidence for a Mechanism Involving Arachidonic Acid Metabolism

J. Dutcher, E. Puszkin, L. Oleksowicz, 1994, Thrombosis and Haemostasis.

Characterization of tumor-induced platelet aggregation: the role of immunorelated GPIb and GPIIb/IIIa expression by MCF-7 breast cancer cells.

E. Schwartz, J. Dutcher, M. Khorshidi, 1995, Thrombosis research.

7113 Radiographic findings of drug-induced pneumonitis and clinical correlation in patients with advanced renal cell carcinoma treated with temsirolimus

C. White, A. Berkenblit, G. Hudes, 2009 .

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Exploratory analysis of the influence of nephrectomy status on temsirolimus efficacy in patients with advanced renal cell carcinoma and poor-risk features

A. Berkenblit, A. Makhson, L. Galand, 2008 .

Sequential axitinib (AG-013736) therapy of patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sunitinib and sorafenib, cytokines and sorafenib, or sorafenib alone

G. Wilding, B. Rini, G. Hudes, 2008 .

Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: evidence for a schedule-dependent effect favoring infusional administration of chemotherapy.

J. Sparano, J. Dutcher, P. Wiernik, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Colonic ischemia complicating immunotherapy with interleukin‐2 and interferon‐alpha

J. Sparano, L. Brandt, J. Dutcher, 1991, Cancer.

Buffy coat platelets stored in apyrase, aprotinin, and ascorbic acid in a suspended bag: combined strategies for reducing platelet activation during storage

J. Dutcher, M. Khorshidi, E. Puszkin, 1996, Transfusion.

Immunotherapy: are we making a difference?

J. Dutcher, 2000, Current opinion in urology.

Alterations in platelet function in patients receiving interleukin-6 as cytokine therapy.

J. Dutcher, E. Puszkin, L. Oleksowicz, 1996, Cancer investigation.

Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production.

J. Leonard, M. Atkins, J. Sosman, 1997, Blood.

Mediastinal osteosarcoma with extension to lungs in a patient treated for Hodgkin's disease

H. Dorfman, J. Dutcher, P. Wiernik, 1988, Cancer.

Is Biochemotherapy the Future

J. Dutcher, P. Wiernik, D. Alexandrescu, 2005 .

Ethiodized oil emulsion 13 in computed tomography of hepatoma.

J. Dutcher, M. Didolkar, P. Wiernik, 1984, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of In Vivo Natural Killer and Lymphokine-Activated Killer Cell Activity in Patients Treated with High-Dose Interleukin-2 and Adoptive Transfer of Autologous LAK Cells

J. Dutcher, E. Paietta, J. Walewski, 1990 .

Phase II trial of prolonged continuous infusion of 5-fluorouracil and interferon-alpha in patients with advanced pancreatic cancer. Eastern Cooperative Oncology Group Protocol 3292.

S. Lipsitz, J. Kirkwood, A. Benson, 1996, American journal of clinical oncology.

Bevacizumab plus interferon-alpha versus interferon-alpha monotherapy in patients with metastatic renal cell carcinoma: Results of overall survival for CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Managing toxicities of high-dose interleukin-2.

J. Dutcher, R. Schwartz, L. Stover, 2002, Oncology.

Phase I S tudy o f R ecombinant H uman C D40 L igand i n Cancer P atients

J. Gribben, J. Dutcher, Jeanne E. Anderson, 2001 .

Long-term follow-up of treatment and potential cure of adult acute lymphocytic leukemia with MOAD: a non-anthracycline containing regimen.

J. Dutcher, E. Paietta, S. Garl, 1993, Leukemia.

Transcription factor E3 and transcription factor EB renal cell carcinomas: clinical features, biological behavior and prognostic factors.

Gudrun Schleiermacher, Jérôme Couturier, Liliane Boccon-Gibod, 2011, The Journal of urology.

Phase II study of alpha2 interferon in the treatment of the chronic myeloproliferative disorders (E5487): a trial of the Eastern Cooperative Oncology Group.

J. Kirkwood, M. Oken, J. Bennett, 2003, Cancer.

The high-dose aldesleukin (HD IL-2) "SELECT" trial in patients with metastatic renal cell carcinoma (mRCC).

R. Figlin, S. Signoretti, M. Atkins, 2010 .

Extramedullary acute promyelocytic leukemia

J. Dutcher, P. Wiernik, R. de Bellis, 1997, Cancer.

Fever and Infection

J. Dutcher, R. Gucalp, 1987 .

Pulmonary Langerhans cell histiocytosis, acute myeloid leukemia, and myelofibrosis in a large family and review of the literature.

J. Dutcher, P. Wiernik, M. Blakley, 2018, Leukemia research.

Labeled cells in patients with malignancy.

J. Dutcher, 1984, Seminars in nuclear medicine.

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer.

R. Figlin, K. Foon, J. Gollob, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Report of a phase I evaluation of dose and schedule of interleukin-1 alpha and cyclophosphamide in patients with advanced tumors: An Eastern Cooperative Oncology Group study (PX990) and review of IL-1-based studies of hematopoietic reconstitution.

D. Neuberg, M. Atkins, S. Wadler, 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

The role of recombinant interleukin-2 in therapy for hematologic malignancies.

J. Dutcher, P. Wiernik, 1993, Seminars in oncology.

Classic case of unicentric mixed-type Castleman's disease.

J. Dutcher, Yanhua Wang, R. Nagubandi, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Idarubicin and standard‐dose cytosine arabinoside in adults with recurrent and refractory acute lymphocytic leukemia

J. Dutcher, E. Paietta, P. Wiernik, 2004, Cancer.

The role of Epstein-Barr virus and elevated levels of tumor necrosis factor in determining prognosis in Asian peripheral T-cell lymphomas.

J. Dutcher, 2003, Leukemia research.

Fulminant metastatic melanoma complicated by a microangiopathic hemolytic anemia.

J. Dutcher, L. Oleksowicz, N. Bhagwati, 1998, Hematopathology and molecular hematology.

PLATELET CRYOPRESERVATION USING DIMETHYL SULFOXIDE

J. Dutcher, C. Schiffer, J. Aisner, 1983, Annals of the New York Academy of Sciences.

Apyrase, ascorbic acid and aprotinin ameliorate the storage lesion in pelleted platelet preparations.

J. Dutcher, E. Puszkin, P. Lalezari, 1997, Biotechnic & histochemistry : official publication of the Biological Stain Commission.

Angiogenesis and melanoma

J. Dutcher, Janice P. Dutcher, 2001, Current oncology reports.

Phase I clinical and pharmacokinetic study of taxol.

R. Lipton, E. Schwartz, J. Dutcher, 1987, Cancer research.

Phase II protocol for the evaluation of new treatments in patients with advanced gastric carcinoma: results of ECOG 5282

D. Haller, J. Dutcher, A. Schutt, 1999, Medical oncology.

Leukocytoclastic vasculitis associated with nizatidine therapy.

J. Dutcher, L. Oleksowicz, J. Suh, 1997, The American journal of medicine.

14 Transfusion Reactions

J. Dutcher, 1987 .

Granulocyte Transfusion Therapy

J. Dutcher, JANICE P. DUTCHER, 1984, The American journal of the medical sciences.

Sustained post‐transfusion granulocyte count increments following transfusion of leukocytes obtained from donors with chronic myelogenous leukemia

J. Dutcher, C. Schiffer, J. Aisner, 1983, American journal of hematology.

20th‐Century Advances in Drug Therapy in Oncology—Part I

J. Dutcher, P. Wiernik, Y. Novik, 2000, Journal of clinical pharmacology.

The potential benefit of granulocyte transfusion therapy.

J. Dutcher, 1989, Cancer investigation.

NIH Consensus conference. Diagnosis and treatment of early melanoma.

E. R. Farmer, William H. Hall, June K Robinson, 1992, JAMA.

The ineffectiveness of random donor platelet transfusion in splenectomized, alloimmunized recipients.

J. Dutcher, C. Schiffer, J. Aisner, 1984, Blood.

Long-term follow-up patients with leukemia receiving platelet transfusions: identification of a large group of patients who do not become alloimmunized.

J. Dutcher, C. Schiffer, J. Aisner, 1981, Blood.

Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group

J. Sosman, G. Weiss, M. Ernstoff, 2002, Journal of Cancer Research and Clinical Oncology.

National Institutes of Health Consensus Development Conference Statement on Diagnosis and Treatment of Early Melanoma, January 27–29, 1992

W. Clark, D. Guerry, N. Swanson, 1993, The American Journal of dermatopathology.

Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry

G. Daniels, M. Morse, J. Dutcher, 2017, Journal of Immunotherapy for Cancer.

Effects of desialylation of ovine submaxillary gland mucin (OSM) on humoral and cellular immune responses to Tn and sialylated Tn.

J. J. Steinberg, J. Dutcher, M. Ramirez, 2006, Cancer immunity.

Metastatic choriocarcinoma in a middle-aged man presenting as a right thigh mass with venous thrombosis

J. Dutcher, P. Wiernik, J. Fuks, 2003, Medical oncology.

Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma

N. Agarwal, M. Fishman, J. Kirkwood, 2016, Cancer Immunology, Immunotherapy.

Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.

J. Sparano, E. Schwartz, J. Dutcher, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ONE Chronic Leukemias and Related Disorders

R. Kyle, J. Dutcher, 2004 .

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.

S. Liou, M. Hidalgo, M. Atkins, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

J. Maroto, C. White, A. Berkenblit, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Terminal transferase positive acute promyelocytic leukemia: in vitro differentiation of a T-lymphocytic/promyelocytic hybrid phenotype.

J. Dutcher, E. Paietta, P. Wiernik, 1985, Blood.

High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993.

R. Fisher, M. Atkins, G. Weiss, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

J. Manola, K. Flaherty, T. Choueiri, 2016, The Lancet.

From melanocytes to melanoma: The progression to malignancy

J. Dutcher, 2006 .

The role of carbonic anhydrase IX overexpression in kidney cancer.

J. Pastorek, J. Dutcher, T. Dorai, 2005, European journal of cancer.

granulocytes to sites of infection Alloimmunization prevents the migration of transfused indium-111- labeled

J. Dutcher, J. Aisner, P. Wiernik, 2011 .

Rapid migration of 111indium-labeled granulocytes to sites of infection.

J. Dutcher, C. Schiffer, G. Johnston, 1981, The New England journal of medicine.

Disease-associated expression profiles in peripheral blood mononuclear cells from patients with advanced renal cell carcinoma.

Manuel Hidalgo, Donna K Slonim, D. Slonim, 2003, Cancer research.

Analysis of PTEN and HIF‐1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon‐α

R. Figlin, A. Berkenblit, A. Strahs, 2009, Cancer.

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

R. Figlin, A. Belldegrun, Su-Chun Cheng, 2014, Clinical Cancer Research.

Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206.

E. Small, B. Rini, J. Rosenberg, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Biphenotypic leukemia with unusual chromosomal translocation in a patient treated for melanoma.

P. Papenhausen, J. Dutcher, E. Paietta, 1986, Cancer genetics and cytogenetics.

Role of Carbonic Anhydrases in the Progression of Renal Cell Carcinoma Subtypes: Proposal of a Unified Hypothesis

J. Pastorek, J. Dutcher, T. Dorai, 2006, Cancer investigation.

Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma

J. Manola, K. Flaherty, M. Atkins, 2019, Clinical Cancer Research.

Adjuvant Treatment for High-Risk Clear Cell Renal Cancer: Updated Results of a High-Risk Subset of the ASSURE Randomized Trial

J. Manola, K. Flaherty, T. Choueiri, 2017, JAMA oncology.

Predicting Renal Cancer Recurrence: Defining Limitations of Existing Prognostic Models With Prospective Trial-Based Validation.

J. Manola, E. Messing, K. Flaherty, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term survival of patients with sarcomatoid renal cell cancer treated with chemotherapy

J. Dutcher, D. Nanus, 2011, Medical oncology.

Identification of predictive biomarkers of overall survival (OS) in patients (pts) with advanced renal cell carcinoma (RCC) treated with interferon alpha (I) with or without bevacizumab (B): Results from CALGB 90206 (Alliance).

Ivo D. Shterev, P. Febbo, E. Small, 2013 .

Phase II trials of high-dose interleukin-2 and lymphokine-activated killer cells in advanced breast carcinoma and carcinoma of the lung, ovary, and pancreas and other tumors.

R. Fisher, M. Atkins, G. Weiss, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Effects of Single-Dose Interleukin-12 Exposure on Interleukin-12–Associated Toxicity and Interferon-γ Production

J. Leonard, M. Atkins, J. Sosman, 1997 .

Targeted therapies and the treatment of non-clear cell renal cell carcinoma.

J. Bellmunt, J. Dutcher, 2013 .

Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial.

R. Figlin, M. Atkins, B. Redman, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of erlotinib in patients with locally advanced or metastatic papillary histology renal cell cancer: SWOG S0317.

W. Samlowski, R. Nagle, P. Mack, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Mammalian target of rapamycin (mTOR) inhibitors

J. Dutcher, Janice P Dutcher, 2004, Current oncology reports.

Innovations and Challenges in Renal Cancer

S. Goldberg, R. Figlin, W. Linehan, 2004, Clinical Cancer Research.

Innovations and Challenges in Renal Cancer: Consensus Statement from the First International Conference

S. Goldberg, R. Figlin, W. Linehan, 2004 .

State-of-the-Art Management of Renal Cell Carcinoma

J. Dutcher, R. Ennis, W. Mourad, 2014, American journal of clinical oncology.

Recent developments in the treatment of renal cell carcinoma

J. Dutcher, 2013, Therapeutic advances in urology.

High-dose interleukin-2 therapy for metastatic renal cell carcinoma and metastatic melanoma: still the standard.

J. Dutcher, 2011, Oncology.

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma.

M. Atkins, J. Sosman, J. Kirkwood, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of temsirolimus versus interferon-α on outcome of patients with advanced renal cell carcinoma of different tumor histologies

R. Figlin, A. Berkenblit, A. Strahs, 2009, Medical oncology.

Management of Patients with Pathologic Variants of Renal Cell Carcinoma: Papillary, Collecting Duct, Medullary and Chromophobe Carcinoma, and Sarcomatoid Differentiation

J. Dutcher, V. Hugec, 2008 .

Renal medullary carcinoma: the Bronx experience.

R. Ghavamian, A. Hakimi, J. Dutcher, 2007, Urology.

Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America

J. Hajdenberg, R. Figlin, J. Hainsworth, 2010, Cancer.

Phase I trial of taxol given as a 24-hour infusion every 21 days: responses observed in metastatic melanoma.

R. Lipton, E. Schwartz, J. Dutcher, 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Yellow skin discoloration associated with sorafenib use for treatment of metastatic renal cell carcinoma.

J. Dutcher, D. Alexandrescu, C. Dasanu, 2007, Southern medical journal.

Targeted therapies and the treatment of non-clear cell renal cell carcinoma.

J. Bellmunt, J. Dutcher, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Carcinoma Mononuclear Cells from Patients with Advanced Renal Cell Disease-associated Expression Profiles in Peripheral Blood

D. Slonim, M. Hidalgo, A. Dorner, 2003 .

A pilot study of alpha-interferon and plicamycin for accelerated phase of chronic myeloid leukemia.

J. Dutcher, E. Paietta, P. Wiernik, 1997, Leukemia research.

Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.

H. Kong, A. Hauschild, M. Atkins, 2008, The oncologist.

Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)

J. Fine, M. Ernstoff, B. Murphy, 2003, Medical oncology.

Novel Management of Pruritus in Patients Treated With IL-2 for Metastatic Renal Cell Carcinoma and Malignant Melanoma

J. Dutcher, M. Baig, S. Lee, 2010, Journal of immunotherapy.

Phase II study of α2 interferon in the treatment of the chronic myeloproliferative disorders (E5487)

J. Kirkwood, M. Oken, J. Bennett, 2003 .

Intravenous Gammaglobulin in Alloimmunized Platelet Transfusion Recipients

J. Dutcher, C. Schiffer, J. Aisner, 2017 .

Experience with sorafenib and the elderly patient

J. Bellmunt, B. Escudier, J. Dutcher, 2010, Medical oncology.

J. Dutcher, P. Etkind, L. Oleksowicz, 1997, Experimental cell research.

High-dose intravenous gammaglobulin in alloimmunized platelet transfusion recipients.

J. Dutcher, C. Schiffer, J. Aisner, 1984, Blood.

Case report: clinical findings and successful resection of melanoma metastatic to the right atrium.

J. Dutcher, R. Brodman, M. Suhrland, 1994, Cancer investigation.

Effects of interleukin‐2 administration on platelet function in cancer patients

J. Dutcher, E. Puszkin, L. Oleksowicz, 1994, American journal of hematology.

Cardiac monitoring of patients receiving arsenic trioxide therapy

J. Dutcher, R. Lucariello, S. Garl, 2004, British journal of haematology.

A systematic collaborative overview of randomized trials comparing idarubicin with daunorubicin (or other anthracyclines) as induction therapy for acute myeloid leukaemia

R. Peto, F. Mandelli, R. Gray, 1998, British journal of haematology.

The prognostic role of detection of circulating melanoma cells in the blood.

J. Dutcher, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

J. Dutcher, R. Lucariello, S. Garl, 2001, Blood.

Update on the biology and management of renal cell carcinoma

J. Dutcher, 2018, Journal of Investigative Medicine.

Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIMSM

N. Agarwal, M. Fishman, S. Patel, 2016, Clinical genitourinary cancer.

A phase I study of cabozantinib (XL184) in patients with renal cell cancer.

W. Kaelin, T. Choueiri, J. Dutcher, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II Study of Interferon Gamma in Malignant Carcinoid Tumors (E9292): A Trial of the Eastern Cooperative Oncology Group

A. Benson, J. Dutcher, J. Erban, 2004, Investigational New Drugs.

A phase II study of taxol in patients with malignant melanoma

D. Trump, J. Dutcher, H. Hochster, 1991, Investigational New Drugs.

Metastatic melanoma

J. Dutcher, Doru T. Alexanrdescu, Peter H. Wrnik, 2005, Medical oncology.

Activity of cabozantinib (XL184) in patients (pts) with metastatic, refractory renal cell carcinoma (RCC).

T. Choueiri, D. Ramies, J. Dutcher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

On the Shoulders of Giants: The Evolution of Renal Cell Carcinoma Treatment-Cytokines, Targeted Therapy, and Immunotherapy.

B. Escudier, J. Dutcher, R. Flippot, 2020, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study.

R. Fisher, M. Atkins, J. Sosman, 1997, The cancer journal from Scientific American.

Treatment of promyelocytic blast crisis of chronic myelogenous leukemia with all trans-retinoic acid.

W. Hittelman, J. Dutcher, E. Paietta, 1991, Leukemia.

Terminal transferase expression in acute myeloid leukaemia: biology and prognosis

P. Papenhausen, J. Dutcher, E. Paietta, 1991, British journal of haematology.

Intensive maintenance therapy improves survival in adult acute nonlymphocytic leukemia: an eight-year follow-up.

J. Dutcher, C. Schiffer, P. Wiernik, 1988, Leukemia.

Acquired glanzmann's thrombasthenia associated with hodgkin's lymphoma

J. Dutcher, L. Oleksowicz, Umekalsoom Malik, 1998, Cancer.

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.

R. Figlin, K. Flaherty, S. Srinivas, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of high-dose interleukin-2 in combination with interferon-alpha 2b.

M. Atkins, G. Weiss, J. Sparano, 1990, Journal of biological response modifiers.

Three phase II cytokine working group trials of gp100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanoma.

B. LaFleur, M. Atkins, J. Sosman, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Cytokine Working Group (CWG) 3-arm phase II trial of gp100 (209–2M) peptide + high dose (HD) Interleukin-2 (IL-2) in HLA-A2+ (A2+) advanced melanoma patients (pts)

Jeffrey W. Clark, M. Atkins, J. Sosman, 2005 .

Adenocarcinoma arising in vulvar breast tissue

C. Runowicz, J. Dutcher, P. Wiernik, 1988, Cancer.

A Phase II Clinical Trial of Interleukin‐2 and Lymphokine‐Activated Killer Cells in Advanced Colorectal Carcinoma

R. Fisher, M. Atkins, J. Doroshow, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

A clinical program of platelet cryopreservation.

J. Dutcher, C. Schiffer, J. Aisner, 1982, Progress in clinical and biological research.

A distinct coagulopathy associated with Interleukin‐2 therapy

J. Sparano, J. Dutcher, I. Sussman, 1994, British journal of haematology.

A Phase 2 Study of Moderate Dose Interleukin-2 and Granulocyte-Macrophage Colony-Stimulating Factor in Patients With Metastatic or Unresectable Renal Cell Carcinoma

J. Dutcher, P. Wiernik, Y. Novik, 2005, Journal of immunotherapy.

Phase I Trial of BAY 50-4798, an Interleukin-2–Specific Agonist in Advanced Melanoma and Renal Cancer

M. Atkins, J. Sosman, M. Ernstoff, 2007, Clinical Cancer Research.

A phase II trial of dose-intensive interleukin-2 in metastatic renal cell carcinoma

J. Dutcher, L. Oleksowicz, 1999, Journal of Cancer Research and Clinical Oncology.

Novel biologic approaches to hematologic malignancies.

J. Dutcher, P. Wiernik, 1999, Cancer treatment and research.

High-Dose R ecombinant I nterleukin 2 T herapy f or P atients With M etastatic M elanoma: A nalysis o f 2 70 P atients Treated B etween 1 985 a nd 1 993

R. Fisher, M. Atkins, G. Weiss, 1999 .

Occurrence of myeloma in a chronic lymphocytic leukemia patients after response to differentiation therapy with interleukin-4.

J. Dutcher, D. Makower, P. Wiernik, 1996, Leukemia & lymphoma.

Polyethylene glycolated interleukin‐2 as maintenance therapy for acute myelogenous leukemia in second remission

J. Dutcher, P. Wiernik, M. Todd, 1994, American journal of hematology.

Hypovitaminosis C in patients treated with high-dose interleukin 2 and lymphokine-activated killer cells.

D. Petrylak, J. Dutcher, E. Paietta, 1991, The American journal of clinical nutrition.

Strokes after intravenous gamma globulin: Thrombotic phenomenon in patients with risk factors or just coincidence?

J. Dutcher, J. Hughes, P. Wiernik, 2005, American journal of hematology.

Levels of soluble interleukin-2 receptors are predictive of response in patients treated with interleukin-2 and lymphokine-activated killer cells

J. Dutcher, E. Paietta, D. Nelson, 1995, Medical oncology.

Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.

R. Fisher, J. Sosman, G. Weiss, 1997, The cancer journal from Scientific American.

A phase II study of the continuous intravenous infusion of interleukin-6 for metastatic renal cell carcinoma.

M. Atkins, J. Sosman, J. Doroshow, 1995, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

High-dose interleukin-2 in metastatic disease: renal cell carcinoma and melanoma.

J. Dutcher, 2002, Oncology.

Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.

J. Dutcher, E. Paietta, S. Hutner, 1987, Cancer research.

Phase I/II Trial of Outpatient PEG-interferon With Interleukin-2 in Advanced Renal Cell Carcinoma: A Cytokine Working Group Study

M. Atkins, J. Sosman, M. Ernstoff, 2007, Journal of immunotherapy.

Characterization of bone metastases in patients with renal cell cancer

J. Dutcher, S. Garl, G.U. Adiga, 2004, BJU international.

Development of two radioimmunoassays to detect paclitaxel in sera and in cerebrospinal, ascitic, and pleural fluids

E. Schwartz, J. Dutcher, S. Horwitz, 1997, Cancer.

Mitoxantrone, vinblastine and CCNU: long-term follow-up of patients treated for advanced and poor-prognosis Hodgkin's disease

J. Dutcher, P. Wiernik, D. Alexandrescu, 2006, Leukemia & lymphoma.

Pilot study of high-dose mitoxantrone and busulfan plus autologous bone transplantation in patients with advanced malignancies.

J. Sparano, J. Dutcher, P. Wiernik, 1995, Bone marrow transplantation.

Association of thyroid disease with acute leukemia

J. Dutcher, C. Moskowitz, P. Wiernik, 1992, American journal of hematology.

Accelerated and blastic phase of chronic myeloid leukemia

J. Dutcher, P. Wiernik, Peter H. Wiernik, 2000, Current treatment options in oncology.

Successful treatment of hairy cell leukemia with β‐ser interferon

J. Dutcher, P. Wiernik, N. Turman, 1990 .

Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis

R. Motzer, G. Wilding, B. Rini, 2013, Journal of clinical pharmacology.

Morphologic and ultrastructural evidence for interleukin‐6 induced platelet activation

J. Dutcher, E. Puszkin, L. Oleksowicz, 1995, American journal of hematology.

Phase I Clinical and Pharmacokinetic Study of Taxol 1

R. Lipton, E. Schwartz, J. Dutcher, 2006 .

Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients with advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN)

A. Berkenblit, A. Strahs, P. Ruff, 2007 .

Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome associated with high-dose interleukin-2 for the treatment of metastatic melanoma.

J. Dutcher, P. Wiernik, D. Alexandrescu, 2005, Journal of immunotherapy.

Lymphoma with primary cardiac manifestations.

M. Steinschneider, J. Ben-Ezra, S. Factor, 1986, American heart journal.

Overview by an oncologist: what are the imaging needs of the oncologist and oncological surgeon?

J. Dutcher, P. Wiernik, R Gucalp, 1997, Seminars in nuclear medicine.

Local Recurrence Following Resection of Intermediate-High Risk Non-metastatic Renal Cell Carcinoma: An Anatomic Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.

J. Manola, E. Messing, K. Flaherty, 2020, The Journal of urology.

Randomized, double-blind phase III study of pazopanib versus placebo in patients with metastatic renal cell carcinoma who have no evidence of disease following metastasectomy: A trial of the ECOG-ACRIN cancer research group (E2810).

N. Agarwal, B. Costello, R. DiPaola, 2019, Journal of Clinical Oncology.

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

M. Milowsky, J. Dutcher, D. Nanus, 2004, Cancer.

Oblimersen and α-interferon in metastatic renal cancer: a phase II study of the California Cancer Consortium

D. Gandara, D. Quinn, P. Frankel, 2007, Journal of Cancer Research and Clinical Oncology.

Phase Ib trial of the effect of peritumoral and intranodal injections of interleukin-2 in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial.

C. Snyderman, J. Kirkwood, J. Johnson, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

Atrasentan in Patients With Advanced Renal Cell Carcinoma: A Phase 2 Trial of the ECOG-ACRIN Cancer Research Group (E6800).

J. Manola, G. Wilding, M. Carducci, 2015, Clinical genitourinary cancer.

Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805)

K. Flaherty, R. DiPaola, R. Uzzo, 2021, Clinical Cancer Research.

Phase II study of all-trans retinoic acid in the accelerated phase or early blastic phase of chronic myeloid leukemia: A study of the Eastern Cooperative Oncology Group (E1993)

J. Bennett, J. Dutcher, E. Paietta, 2005, Leukemia & lymphoma.

Management of hepatitis B in the era of checkpoint inhibition

J. Dutcher, 2020, Journal for ImmunoTherapy of Cancer.

Cardiovascular considerations with anthracycline use in patients with cancer.

W. Frishman, J. Dutcher, D. Keefe, 2001, Heart disease.

Modern transfusion therapy

J. Dutcher, 1990 .

A Cytokine Working Group phase II study of temozolomide (TMZ), thalidomide (THAL) and whole brain radiation therapy (WBRT) for patients with brain metastases from melanoma

Jeffrey W. Clark, M. Atkins, J. Sosman, 2005 .

ECOG 8802: Phase II trial of doxorubicin (Dox) and gemcitabine (Gem) in metastatic renal cell carcinoma (RCC) with sarcomatoid features.

J. Manola, G. Wilding, E. Heath, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma.

J. Manola, E. Messing, K. Flaherty, 2021, European urology.

Phase I Clinical and Pharmacokinetic Study of Taxol1

R. Lipton, E. Schwartz, J. Dutcher, 2006 .

Effect of Renal Impairment on the Pharmacokinetics and Safety of Axitinib

R. Motzer, G. Wilding, B. Rini, 2015, Targeted Oncology.

Survival after phase II treatment of advanced renal cell carcinoma with taxol or high-dose interleukin-2.

J. Sparano, J. Dutcher, E. Paietta, 1993, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

The BEST trial (E2804): A randomized phase II study of VEGF, RAF kinase, and mTOR combination targeted therapy (CTT) with bevacizumab (bev), sorafenib (sor), and temsirolimus (tem) in advanced renal cell carcinoma (RCC).

J. Manola, K. Flaherty, M. Atkins, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II Study of Interleukin-4 in Indolent B-cell Non-Hodgkin Lymphoma and B-cell Chronic Lymphocytic Leukemia: A Study of the Eastern Cooperative Oncology Group (E5Y92)

J. Dutcher, C. Falkson, J. Rowe, 2010, Journal of immunotherapy.

A REVIEW OF THE NEW CYTOKINES: IL‐4, IL‐6, IL‐11, AND IL‐12

J. Dutcher, L. Oleksowicz, 1994, American journal of therapeutics.

Interleukin-2 Can Cure Kidney Cancer.

J. Dutcher, P. Wiernik, 2018, The oncologist.

Phase II Trial of Recombinant Alpha‐2b‐Interferon and Low‐Dose Cyclophosphamide in Advanced Melanoma and Renal Cell Carcinoma

J. Dutcher, N. Ciobanu, L. Landau, 1988, American journal of clinical oncology.

Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.

Su-Chun Cheng, S. Signoretti, B. Leibovich, 2013 .

Occurrence of renal cell carcinoma and hematologic malignancies (predominantly lymphoid) in individuals and in families

J. Dutcher, Leticia Varella, P. Wiernik, 2016, Familial Cancer.

Hematologic abnormalities in patients with nonhematologic malignancies.

J. Dutcher, 1987, Hematology/oncology clinics of North America.

The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Subset analysis of patients (pts) with brain metastases (BM)

R. Figlin, R. Bukowski, W. Stadler, 2007 .

Life-threatening hyperleukocytosis and pulmonary compromise after priming with recombinant human granulocyte-macrophage colony-stimulating factor in a patient with acute myelomonocytic leukemia.

J. Dutcher, A. Einzig, P. Wiernik, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A novel technique for preparing improved buffy coat platelet concentrates.

J. Dutcher, E. Puszkin, P. Lalezari, 1995, Blood cells, molecules & diseases.

Impact of histology on the treatment outcome of metastatic or recurrent renal cell carcinoma

J. Dutcher, G. Caliendo, Jing‐Tang Wu, 1998, Medical oncology.

Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program

J. Hajdenberg, R. Figlin, J. Hainsworth, 2010, Oncology.

4507 ORAL Axitinib (AG-013736; AG) in patients (pts) with metastatic clear cell renal cell cancer (RCC) refractory to sorafenib

G. Wilding, B. Rini, P. Bycott, 2007 .

Cardiac safety analysis for a phase III trial of sunitinib (SU) or sorafenib (SO) or placebo (PLC) in patients (pts) with resected renal cell carcinoma (RCC).

J. Manola, K. Flaherty, M. Atkins, 2012 .

Phase II trial of merbarone in patients with malignant brain tumors

J. Dutcher, R. Mitnick, P. Wiernik, 1997, Medical oncology.

First-line treatment with bevacizumab (B) and high dose (HD) bolus aldesleukin (IL-2) in metastatic renal cell carcinoma (mRCC) patients (Pts)

M. Atkins, J. Sosman, M. Regan, 2007 .

Thomas F. Gajewski and F. Stephen Hodi (eds): Targeted therapeutics in melanoma. Current clinical oncology, Series edited by Maurie Markman

J. Dutcher, Janice P. Dutcher, 2013, Medical Oncology.

Adherence to oral therapies among patients with renal cell carcinoma: Post hoc analysis of the ECOG‐ACRIN E2805 trial

R. DiPaola, D. Gerber, C. Murphy, 2021, Cancer medicine.

Histocompatible platelet transfusion for patients with leukemia

J. Dutcher, C. Schiffer, J. Aisner, 1982 .

Results From a Randomized Phase II Trial of Sunitinib and Gemcitabine or Sunitinib in Advanced Renal Cell Carcinoma with Sarcomatoid Features: ECOG-ACRIN E1808.

J. Manola, E. Plimack, R. DiPaola, 2023, Clinical genitourinary cancer.

Randomized phase II study of two different doses of AVE0005 (VEGF Trap, aflibercept) in patients (pts) with metastatic renal cell carcinoma (RCC): An ECOG-ACRIN study [E4805].

J. Manola, R. DiPaola, M. Carducci, 2015 .

Taxol produces a predominantly sensory neuropathy

R. Lipton, J. Dutcher, J. Kaplan, 1989, Neurology.

CD40 ligand therapy of lymphoma patients.

J. Gribben, A. Younes, J. Dutcher, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma.

R. Fisher, M. Atkins, J. Doroshow, 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

NCI 6896: A phase I trial of suberoylanilide hydroxamic acid (SAHA) and 13-cis retinoic acid in the treatment of patients with advanced renal cell carcinoma (RCC).

M. Mazumdar, M. Milowsky, J. Dutcher, 2011, Journal of Clinical Oncology.

Phase I clinical and pharmacokinetic study of menogaril (7-con-O-methylnogarol) in previously treated patients with acute leukemia

Edward L. Schwartz, Laura Benson, E. Schwartz, 1993, Investigational New Drugs.

Novel Management of Pruritus in Patients Treated With IL-2 for Metastatic Renal Cell Carcinoma and Malignant Melanoma

J. Dutcher, M. Baig, S. Lee, 2010, Journal of immunotherapy.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two

Charles J. Vaske, Joe Y. Chang, Scott R. Presnell, 2016, Journal for ImmunoTherapy of Cancer.

D. Neuberg, M. Atkins, S. Wadler, 2014, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.

R. Fisher, G. Weiss, J. Dutcher, 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Bleeding and Coagulopathy

J. Dutcher, 1987 .

Temsirolimus for advanced renal cell carcinoma (RCC): Compassionate versus commercial use

J. Dutcher, S. Graham, P. Bojanapally, 2008 .